Gilead Sciences competitorsClear all

Gilead Sciences's top competitors include Novo Nordisk, Catalent, Biogen, ViiV Healthcare, Novartis, Bristol-Myers Squibb, AbbVie and Merck Group.
Gilead Sciences
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Novo Nordisk
Novo Nordisk
Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products.
Catalent
Catalent
Catalent Pharma Solutions is a company providing integrated services, drug delivery technologies, and manufacturing solutions.
Biogen
Biogen
Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.
ViiV Healthcare
ViiV Healthcare
ViiV Healthcare is a company focused on research and development of medicines for people living with HIV.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with serious and life-threatening diseases.
AbbVie
AbbVie
AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Merck Group
Merck Group
Merck Group is a pharmaceutical, chemical, and life sciences company.
Founding Date
Founding Date
1987
Founding Date
1923
Founding Date
2007
Founding Date
1978
Founding Date
2009
Founding Date
1996
Founding Date
1887
Founding Date
2013
Founding Date
1668
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Foster City, US HQ
Abb, AR
Melbourne, AU
Wien, AT
Machelen, BE
São Paulo, BR
Edmonton, CA
see more
Locations
Bagsværd, DK HQ
Tirana, AL
Tizi Ouzou, DZ
Buenos Aires, AR
Baulkham Hills, AU
Wien, AT
Baku, AZ
see more
Locations
Franklin Township, US HQ
Loma Hermosa, AR
Bruxelles, BE
Charleroi, BE
Charleroi, BE
Indaiatuba, BR
Sorocaba, BR
see more
Locations
Cambridge, US HQ
Vicente López, AR
Macquarie Park, AU
Wien, AT
Machelen, BE
Mississauga, CA
see more
Locations
London, GB HQ
Abbotsford, AU
Wavre, BE
Laval, CA
Marly Le Roi, FR
München, DE
see more
Locations
Basel, CH HQ
Tirana, AL
Bir Mourad Raïs, DZ
Duc, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
see more
Locations
New York, US HQ
Braine L'alleud, BE
Montréal, CA
Pudong Xinqu, CN
Virum, DK
Espoo, FI
Rueil Malmaison, FR
see more
Locations
Lake Bluff, US HQ
Alger, DZ
Buenos Aires, AR
Mascot, AU
Wien, AT
Wavre, BE
Sarajevo, BA
see more
Locations
Darmstadt, DE HQ
Hydra, DZ
Csd, AR
Bayswater, AU
Bayswater, AU
Macquarie Park, AU
Wien, AT
see more
Employees
Employees
11,8007% increase
Employees
44,3262% increase
Employees
13,90013% increase
Employees
7,4005% decrease
Employees
1,3481% increase
Employees
105,7942% increase
Employees
30,00029% increase
Employees
29,1601% decrease
Employees
58,1272% increase
Valuation ($)
Valuation ($)
86.6 b
Valuation ($)
N/A
Valuation ($)
18.6 b
Valuation ($)
59.6 b
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
150.4 b
Valuation ($)
203.7 b
Valuation ($)
N/A
Twitter followers
Twitter followers
67.9 k
Twitter followers
38.1 k
Twitter followers
18.7 k
Twitter followers
39.2 k
Twitter followers
15.4 k
Twitter followers
291.5 k
Twitter followers
151.3 k
Twitter followers
70.8 k
Twitter followers
20.7 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
19
Number of tweets (last 30 days)
37
Number of tweets (last 30 days)
140
Number of tweets (last 30 days)
60
Number of tweets (last 30 days)
77
Number of tweets (last 30 days)
7
Number of tweets (last 30 days)
75
Number of tweets (last 30 days)
59
Number of tweets (last 30 days)
83
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
25.3
Average likes per tweet (last 30 days)
8.9
Average likes per tweet (last 30 days)
0.9
Average likes per tweet (last 30 days)
18.5
Average likes per tweet (last 30 days)
5.2
Average likes per tweet (last 30 days)
5.3
Average likes per tweet (last 30 days)
7.7
Average likes per tweet (last 30 days)
7.4
Average likes per tweet (last 30 days)
2.4
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
70.27%
Percentage of tweets with engagement (last 30 days)
55.71%
Percentage of tweets with engagement (last 30 days)
98.33%
Percentage of tweets with engagement (last 30 days)
98.7%
Percentage of tweets with engagement (last 30 days)
28.57%
Percentage of tweets with engagement (last 30 days)
97.33%
Percentage of tweets with engagement (last 30 days)
96.61%
Percentage of tweets with engagement (last 30 days)
95.18%
Alexa Website Rank
Alexa Website Rank
112610
Alexa Website Rank
192672
Alexa Website Rank
335605
Alexa Website Rank
289178
Alexa Website Rank
427084
Alexa Website Rank
88970
Alexa Website Rank
101235
Alexa Website Rank
96656
Alexa Website Rank
150790
Employee Rating
Employee Rating
3.8
Employee Rating
4.1
Employee Rating
3.5
Employee Rating
4.2
Employee Rating
3.5
Employee Rating
4.2
Employee Rating
4.1
Employee Rating
4
Employee Rating
4.1

Financial

Revenue (est.)
Revenue (est.)
$24.7b (FY, 2020)
Revenue (est.)
kr122b (FY, 2019)
Revenue (est.)
$3.1b (FY, 2020)
Revenue (est.)
$13.4b (FY, 2020)
Revenue (est.)
N/A
Revenue (est.)
$48.7b (FY, 2020)
Revenue (est.)
$42.5b (FY, 2020)
Revenue (est.)
$45.8b (FY, 2020)
Revenue (est.)
€17.5b (FY, 2020)
Cost of goods
Cost of goods
$4.6b (FY, 2020)
Cost of goods
kr20.1b (FY, 2019)
Cost of goods
$2.1b (FY, 2020)
Cost of goods
$1.8b (FY, 2020)
Cost of goods
N/A
Cost of goods
$15.1b (FY, 2020)
Cost of goods
$11.8b (FY, 2020)
Cost of goods
$15.4b (FY, 2020)
Cost of goods
€6.8b (FY, 2020)
Gross profit
Gross profit
$20.1b (FY, 2020)
Gross profit
kr101.9b (FY, 2019)
Gross profit
$983.3m (FY, 2020)
Gross profit
$11.6b (FY, 2020)
Gross profit
N/A
Gross profit
$33.5b (FY, 2020)
Gross profit
$30.7b (FY, 2020)
Gross profit
$30.4b (FY, 2020)
Gross profit
€10.7b (FY, 2020)
Net income
Net income
$89m (FY, 2020)
Net income
kr39b (FY, 2019)
Net income
$220.7m (FY, 2020)
Net income
$4.1b (FY, 2020)
Net income
N/A
Net income
$8.1b (FY, 2020)
Net income
($9b) (FY, 2020)
Net income
$4.6b (FY, 2020)
Net income
€2b (FY, 2020)

Operating

Countries
Countries
35 (FY, 2019)
Countries
N/A
Countries
85 (FY, 2020)
Countries
N/A
Countries
N/A
Countries
N/A
Countries
N/A
Countries
175 (FY, 2019)
Countries
66 (FY, 2020)
Manufacturing Facilities
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
7 (FY, 2019)
Manufacturing Facilities
14 (FY, 2019)
Manufacturing Facilities
N/A
Patents (US)
Patents (US)
650 (Dec, 2020)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
21 (FY, 2019)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Phase I Trials Products (Immunology)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
5 (FY, 2019)
Phase I Trials Products (Immunology)
2 (Mar, 2020)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
7 (FY, 2019)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
19 (FY, 2019)
Phase I Trials Products (Oncology)
18 (Mar, 2020)
Phase I Trials Products (Oncology)
N/A
Phase I/II Trials Products
Phase I/II Trials Products
N/A
Phase I/II Trials Products
N/A
Phase I/II Trials Products
N/A
Phase I/II Trials Products
1 (FY, 2017)
Phase I/II Trials Products
N/A
Phase I/II Trials Products
118 (Q4, 2020)
Phase I/II Trials Products
N/A
Phase I/II Trials Products
N/A
Phase I/II Trials Products
N/A
Phase II Trials Products (Immunology)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
4 (FY, 2019)
Phase II Trials Products (Immunology)
6 (Mar, 2020)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
2 (FY, 2019)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
14 (FY, 2019)
Phase II Trials Products (Oncology)
3 (Mar, 2020)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Other)
Phase II Trials Products (Other)
1 (FY, 2018)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
2 (Mar, 2020)
Phase II Trials Products (Other)
N/A
Phase III Trials Products
Phase III Trials Products
27 (FY, 2019)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
6 (Q3, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
44 (Q4, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products (Immunology)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
4 (FY, 2019)
Phase III Trials Products (Immunology)
11 (Mar, 2020)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
1 (FY, 2019)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
22 (Q4, 2020)
Phase III Trials Products (Oncology)
9 (FY, 2019)
Phase III Trials Products (Oncology)
13 (Mar, 2020)
Phase III Trials Products (Oncology)
N/A
Products
Products
24 (FY, 2019)
Products
N/A
Products
7 k (FY, 2020)
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Products
300 k (FY, 2020)
Research and Development Centers
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
12 (FY, 2019)
Research and Development Centers
8 (FY, 2019)
Research and Development Centers
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 6.5m
Total funding raised
$ 15.5m
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

Novo Nordisk
HQ
Bagsværd, DK
Employees
44,326↑ 2% increase

Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products.

View company
Catalent
HQ
Franklin Township, US
Employees
13,900↑ 13% increase

Catalent Pharma Solutions is a company providing integrated services, drug delivery technologies, and manufacturing solutions.

View company
Biogen
HQ
Cambridge, US
Employees
7,400↓ 5% decrease

Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.

View company
ViiV Healthcare
HQ
London, GB

ViiV Healthcare is a company focused on research and development of medicines for people living with HIV.

View company